Scott M. Rocklage is currently the Managing Partner of 5 AM ventures since 2004. He has a Bachelors of Science in Chemistry from the University of California, Berkeley. He also received his Ph.D. from the Massachusets College.
He has over 30 years of experience in the Healthcare industry. He does the role of strategic management in the 5 AM Ventures and is currently based in Waltham, MA office.
Dr. Rocklage has also served as the group director of Cubist Pharmaceuticals. He is also the president of Nycomed Salutar and also the Chairman of an organization called Nycomed Interventional.He has also been able to help in the Drugs associated application by FDA. He is also the Board Chairman of Achaogen, Relypsa, and Semprus. He also works on the boards of WaveRx, Variation, and Pulmatrix. He also serves as a Board of Associates at the Whitehead Institute.
He is also the Chief executive officer of Amersham Health. has held so many positions in his tenure as a health specialist. He served at the Board of Ciara as the Chairman, chairman of Novira Therapeutics since August 2013. He also serves on the Board of Kinestral. He has also served on the board of EPIRUS BioPharmaceuticals.
Scott believes his business and his life and science. He is always focused on working with Boards and strategizing on the way forward.
Dr. Scott M. Rocklage believes in working with entrepreneurs who are either physicians, scientists or even businessmen that will help them come up with potential medicines that fulfill future medical needs.
He is a very good time manager who times considerations and how he prioritizes his activities. He believes in advance calendaring of the future events. He has a special focus to many people and has the desire and the urge to help new companies during start-ups. His vast and wide experience make this a good business startup advisor. Learn more about Scott Rockledge: http://chemistry.mit.edu/scott-rocklage-phd-2-and-his-wife-patty-are-celebrated-their-major-gift
He is time conscious and a great health expert in the pharmaceutical Boards. He has kept on joining several boards and has worked closely with World experts who work with the ambition of strengthening the ties in the medical industry.